Praxis Precision Medicines, Inc. (PRAX)
D
Pipeline Grade
Financial Position (from SEC Filings)
$536.8M
Cash & Equivalents
$86.2M
Quarterly Burn Rate
19 mo
Est. Cash Runway
$9,060M
Market Cap
Estimated from most recent SEC quarterly filing. View SEC filings
Drug Pipeline (0 Assets)
No drugs indexed yet. Pipeline data is populated from ClinicalTrials.gov and openFDA.
Upcoming Catalysts
| Date | Event | Drug |
|---|---|---|
| 2026-09-27 | Pdufa | — |
| 2027-01-25 | Phase3 Readout | — |
| 2027-01-29 | Pdufa | — |
| 2027-06-01 | Phase3 Readout | — |
Active Clinical Trials (5)
| NCT # | Title | Phase | Status | Enrollment |
|---|---|---|---|---|
| NCT07076199 | A Research Study to See How a Weekly Insulin, Insulin Icodec, Helps in Reducing the Blood Sugar Compared to Daily Insuli... | PHASE3 | Recruiting | 877 |
| NCT06091865 | A Study to Compare How Well Odronextamab Combined With Chemotherapy Works and How Safe it is Against Rituximab Combined ... | PHASE3 | Recruiting | 904 |
| NCT06091254 | A Trial to Learn if Odronextamab is Safe and Well-Tolerated and How Well it Works Compared to Rituximab Combined With Di... | PHASE3 | Recruiting | 822 |
| NCT06532006 | A Phase Ⅲ Clinical Study of HLX22 in Combination With Trastuzumab and Chemotherapy for the Treatment of Gastroesophage... | PHASE3 | Recruiting | 550 |
| NCT04232553 | A Long-term Extension Study of Mirikizumab (LY3074828) in Participants With Crohn's Disease | PHASE3 | Active Not Recruiting | 996 |
Source: ClinicalTrials.gov. Trial status last updated by sponsor — may not reflect current state.